NetworkNewsBreaks – Zogenix, Inc. (NASDAQ: ZGNX) Featured in Mizuho Securities Research Report
Zogenix, Inc. (NASDAQ: ZGNX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Zogenix reported earnings yesterday. 4Q19 EPS was $(1.26) vs. FactSet consensus of $(1.04) and FY19 EPS was $(9.74) vs. consensus of $(9.54). We do not see earnings as the most important value driver for ZGNX at this stage. Importantly, we remain confident in the potential FDA approval of FINTEPLA for the treatment of Dravet syndrome (PDUFA: 06/25/20). On yesterday's call, management highlighted two-year interim data showing long-term reductions in seizure frequency, supporting our view that FINTEPLA may be differentiated…







